Normosang (Human Hemin)

Human hemin supplies the body with heme, which binds to and down‑regulates aminolevulinic acid synthase (ALAS), the first enzyme in the heme‑biosynthetic pathway. This feedback inhibition limits the production of δ‑aminolevulinic acid and porphobilinogen, thereby decreasing the accumulation of neurotoxic intermediates that cause porphyria symptoms.

The dose of Normosang is individualized and set by the treating physician based on the severity of the porphyria attack, the patient’s weight, renal and hepatic function, and response to therapy. No fixed dosing regimen is provided here; prescribers follow clinical guidelines and patient‑specific factors.

Safety data for human hemin in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Normosang, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

The principal alternative to human hemin is high‑dose glucose infusion, which works by suppressing ALAS indirectly. Direct hemin therapy, such as Normosang, provides a more rapid and specific reduction of porphyrin precursors. Another hemin product (e.g., Panhematin) is chemically similar; differences lie mainly in formulation, regulatory status and supply chain.

Normosang must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The lyophilized powder should be reconstituted with the appropriate diluent immediately before use, and the prepared solution should be administered promptly according to aseptic technique.

The lyophilized powder is reconstituted with a sterile diluent to create a clear solution, which is then infused intravenously over a period typically ranging from 30 minutes to several hours, depending on the prescribed dose and patient tolerance. Administration is performed under medical supervision in a setting equipped for emergency management.

The most serious adverse reactions include anaphylactic or severe allergic responses, hemolysis (especially in patients with glucose‑6‑phosphate dehydrogenase deficiency), and acute renal failure. Early recognition of symptoms such as sudden hypotension, respiratory distress, dark urine, or rapid decline in kidney function is essential for prompt intervention.

Normosang should be avoided in individuals with known hypersensitivity to human hemin or any excipients, patients with G6PD deficiency due to the risk of hemolysis, and in those with severe hepatic or renal impairment unless a specialist determines that benefits outweigh risks. Use under specialist guidance is recommended for all patients.